| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infertility, Male | 18 | 2024 | 295 | 5.640 |
Why?
|
| Erectile Dysfunction | 20 | 2026 | 197 | 5.160 |
Why?
|
| Testosterone | 25 | 2025 | 590 | 4.100 |
Why?
|
| Spermatozoa | 12 | 2026 | 254 | 2.430 |
Why?
|
| Penile Prosthesis | 7 | 2024 | 41 | 2.220 |
Why?
|
| Varicocele | 6 | 2021 | 60 | 2.110 |
Why?
|
| Azoospermia | 7 | 2026 | 53 | 1.860 |
Why?
|
| Semen | 5 | 2022 | 84 | 1.650 |
Why?
|
| Hypogonadism | 13 | 2025 | 324 | 1.610 |
Why?
|
| Priapism | 2 | 2024 | 11 | 1.570 |
Why?
|
| Sexual Dysfunction, Physiological | 6 | 2024 | 83 | 1.560 |
Why?
|
| Sperm Injections, Intracytoplasmic | 9 | 2021 | 50 | 1.540 |
Why?
|
| Sperm Count | 11 | 2026 | 100 | 1.520 |
Why?
|
| Extracorporeal Shockwave Therapy | 4 | 2026 | 10 | 1.460 |
Why?
|
| Genetic Testing | 6 | 2022 | 1088 | 1.380 |
Why?
|
| Male | 95 | 2026 | 64765 | 1.370 |
Why?
|
| Databases, Factual | 6 | 2024 | 1225 | 1.310 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 3 | 2020 | 15 | 1.290 |
Why?
|
| Semen Analysis | 7 | 2026 | 43 | 1.250 |
Why?
|
| Fertilization in Vitro | 8 | 2021 | 143 | 1.250 |
Why?
|
| Urology | 5 | 2023 | 80 | 1.150 |
Why?
|
| Hormone Replacement Therapy | 4 | 2024 | 214 | 1.120 |
Why?
|
| Androgens | 5 | 2024 | 264 | 1.080 |
Why?
|
| Penile Erection | 7 | 2023 | 79 | 1.070 |
Why?
|
| Sperm Motility | 7 | 2022 | 113 | 1.060 |
Why?
|
| Ejaculation | 2 | 2024 | 19 | 1.030 |
Why?
|
| Penile Implantation | 5 | 2024 | 25 | 1.030 |
Why?
|
| Humans | 108 | 2026 | 130959 | 1.010 |
Why?
|
| Vasectomy | 2 | 2023 | 16 | 0.970 |
Why?
|
| Shift Work Schedule | 6 | 2025 | 29 | 0.950 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 295 | 0.900 |
Why?
|
| Penile Induration | 6 | 2023 | 38 | 0.870 |
Why?
|
| Propensity Score | 6 | 2025 | 270 | 0.850 |
Why?
|
| Internship and Residency | 5 | 2023 | 1217 | 0.850 |
Why?
|
| Lower Urinary Tract Symptoms | 5 | 2021 | 40 | 0.840 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 40 | 0.830 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2019 | 68 | 0.820 |
Why?
|
| Spermatogenesis | 3 | 2024 | 168 | 0.810 |
Why?
|
| Fertility | 2 | 2023 | 258 | 0.790 |
Why?
|
| Vasoconstrictor Agents | 1 | 2024 | 137 | 0.790 |
Why?
|
| Analgesics, Opioid | 5 | 2023 | 470 | 0.780 |
Why?
|
| Schools, Medical | 2 | 2021 | 114 | 0.770 |
Why?
|
| Oligospermia | 2 | 2019 | 65 | 0.740 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 4 | 2025 | 24 | 0.730 |
Why?
|
| Genetic Counseling | 3 | 2022 | 237 | 0.730 |
Why?
|
| Polycythemia | 1 | 2022 | 45 | 0.730 |
Why?
|
| Insurance | 1 | 2022 | 8 | 0.730 |
Why?
|
| Abortion, Induced | 1 | 2023 | 88 | 0.720 |
Why?
|
| Quality of Life | 9 | 2023 | 2092 | 0.710 |
Why?
|
| Chorionic Gonadotropin | 2 | 2024 | 78 | 0.700 |
Why?
|
| Urogenital Neoplasms | 2 | 2020 | 11 | 0.700 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 6 | 0.690 |
Why?
|
| Job Application | 1 | 2021 | 21 | 0.690 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 4 | 2024 | 34 | 0.670 |
Why?
|
| Social Media | 1 | 2023 | 119 | 0.670 |
Why?
|
| Weight Loss | 1 | 2024 | 526 | 0.640 |
Why?
|
| School Admission Criteria | 1 | 2020 | 30 | 0.640 |
Why?
|
| Allografts | 1 | 2021 | 219 | 0.630 |
Why?
|
| Middle Aged | 35 | 2025 | 28553 | 0.630 |
Why?
|
| Fertility Preservation | 4 | 2022 | 61 | 0.620 |
Why?
|
| Adult | 37 | 2025 | 31296 | 0.620 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 46 | 0.610 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2019 | 17 | 0.600 |
Why?
|
| Abortion, Spontaneous | 2 | 2019 | 82 | 0.590 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 364 | 0.590 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 375 | 0.590 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 97 | 0.590 |
Why?
|
| Spermatic Cord Torsion | 1 | 2019 | 16 | 0.590 |
Why?
|
| Prevalence | 8 | 2024 | 2692 | 0.590 |
Why?
|
| Papillomaviridae | 1 | 2020 | 178 | 0.580 |
Why?
|
| United States | 16 | 2024 | 11852 | 0.570 |
Why?
|
| Retrospective Studies | 30 | 2026 | 17763 | 0.570 |
Why?
|
| Prostatic Hyperplasia | 4 | 2025 | 115 | 0.560 |
Why?
|
| Obesity | 4 | 2024 | 2389 | 0.550 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 174 | 0.550 |
Why?
|
| Insemination | 1 | 2017 | 2 | 0.550 |
Why?
|
| Pregnancy Outcome | 3 | 2019 | 628 | 0.550 |
Why?
|
| Penis | 4 | 2024 | 83 | 0.540 |
Why?
|
| Mass Screening | 2 | 2020 | 807 | 0.520 |
Why?
|
| Pregnancy Rate | 5 | 2020 | 34 | 0.510 |
Why?
|
| Antidepressive Agents | 3 | 2024 | 328 | 0.510 |
Why?
|
| Fertility Agents, Male | 1 | 2016 | 6 | 0.510 |
Why?
|
| Telomere | 1 | 2018 | 220 | 0.510 |
Why?
|
| Heterozygote | 1 | 2019 | 722 | 0.490 |
Why?
|
| Aneuploidy | 2 | 2019 | 137 | 0.490 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 2648 | 0.490 |
Why?
|
| Men | 1 | 2016 | 7 | 0.490 |
Why?
|
| Abortion, Habitual | 1 | 2016 | 15 | 0.480 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 998 | 0.480 |
Why?
|
| Neoplasms | 3 | 2021 | 2964 | 0.470 |
Why?
|
| Stroke | 1 | 2023 | 1056 | 0.460 |
Why?
|
| Hospitalization | 1 | 2024 | 1935 | 0.450 |
Why?
|
| Pregnancy | 13 | 2023 | 7500 | 0.440 |
Why?
|
| Hematocrit | 3 | 2023 | 105 | 0.430 |
Why?
|
| Chromosome Deletion | 4 | 2021 | 653 | 0.420 |
Why?
|
| Young Adult | 14 | 2024 | 10016 | 0.410 |
Why?
|
| Risk Factors | 9 | 2024 | 11022 | 0.400 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 2100 | 0.400 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2024 | 41 | 0.390 |
Why?
|
| Treatment Outcome | 16 | 2026 | 12956 | 0.390 |
Why?
|
| Mutation | 4 | 2023 | 6147 | 0.370 |
Why?
|
| Aged | 18 | 2025 | 21005 | 0.360 |
Why?
|
| Male Urogenital Diseases | 3 | 2023 | 15 | 0.360 |
Why?
|
| Sex Chromosome Aberrations | 3 | 2020 | 59 | 0.350 |
Why?
|
| Chromosomes, Human, Y | 3 | 2020 | 53 | 0.350 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2022 | 94 | 0.340 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2022 | 101 | 0.340 |
Why?
|
| Stem Cell Transplantation | 2 | 2026 | 234 | 0.340 |
Why?
|
| Sperm Retrieval | 2 | 2021 | 12 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 773 | 0.320 |
Why?
|
| Cystic Fibrosis | 2 | 2023 | 267 | 0.300 |
Why?
|
| Work Schedule Tolerance | 2 | 2020 | 39 | 0.300 |
Why?
|
| Teratozoospermia | 2 | 2019 | 5 | 0.300 |
Why?
|
| High-Energy Shock Waves | 2 | 2019 | 7 | 0.280 |
Why?
|
| Incidence | 4 | 2024 | 3360 | 0.280 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 3825 | 0.270 |
Why?
|
| Female | 24 | 2025 | 70720 | 0.270 |
Why?
|
| Bupropion | 2 | 2024 | 26 | 0.260 |
Why?
|
| Depression | 3 | 2025 | 1320 | 0.260 |
Why?
|
| Drug Prescriptions | 3 | 2023 | 230 | 0.260 |
Why?
|
| Clinical Trials as Topic | 3 | 2023 | 1129 | 0.250 |
Why?
|
| Chromatin | 2 | 2021 | 502 | 0.250 |
Why?
|
| Ultrasonic Therapy | 1 | 2026 | 27 | 0.240 |
Why?
|
| Pandemics | 4 | 2023 | 1155 | 0.240 |
Why?
|
| Image Cytometry | 1 | 2026 | 18 | 0.240 |
Why?
|
| Benzodiazepines | 2 | 2023 | 106 | 0.240 |
Why?
|
| Platelet-Rich Plasma | 1 | 2026 | 23 | 0.240 |
Why?
|
| Ablation Techniques | 1 | 2025 | 30 | 0.230 |
Why?
|
| Congenital Abnormalities | 2 | 2019 | 326 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2023 | 5100 | 0.230 |
Why?
|
| Urinary Diversion | 1 | 2025 | 16 | 0.220 |
Why?
|
| Telemedicine | 2 | 2023 | 513 | 0.220 |
Why?
|
| Vas Deferens | 2 | 2023 | 21 | 0.220 |
Why?
|
| DNA Fragmentation | 2 | 2021 | 55 | 0.220 |
Why?
|
| Hirsutism | 1 | 2024 | 24 | 0.210 |
Why?
|
| Water | 1 | 2025 | 185 | 0.210 |
Why?
|
| Geography | 2 | 2021 | 117 | 0.210 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2024 | 182 | 0.210 |
Why?
|
| Cystectomy | 1 | 2025 | 146 | 0.210 |
Why?
|
| Adolescent | 9 | 2024 | 20817 | 0.210 |
Why?
|
| Vulvar Lichen Sclerosus | 1 | 2023 | 9 | 0.200 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2024 | 78 | 0.200 |
Why?
|
| Acidosis | 1 | 2025 | 98 | 0.200 |
Why?
|
| Flow Cytometry | 1 | 2026 | 772 | 0.200 |
Why?
|
| Female Urogenital Diseases | 1 | 2023 | 8 | 0.200 |
Why?
|
| Epispadias | 1 | 2023 | 2 | 0.200 |
Why?
|
| Hernia, Inguinal | 1 | 2023 | 39 | 0.200 |
Why?
|
| Journal Impact Factor | 1 | 2023 | 26 | 0.200 |
Why?
|
| Bladder Exstrophy | 1 | 2023 | 13 | 0.200 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2023 | 33 | 0.190 |
Why?
|
| Abortion, Legal | 1 | 2023 | 18 | 0.190 |
Why?
|
| Bibliometrics | 1 | 2023 | 39 | 0.190 |
Why?
|
| Metformin | 1 | 2025 | 169 | 0.190 |
Why?
|
| Central Nervous System Stimulants | 1 | 2023 | 129 | 0.190 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2022 | 11 | 0.190 |
Why?
|
| Betacoronavirus | 3 | 2020 | 285 | 0.190 |
Why?
|
| beta-Thalassemia | 1 | 2022 | 26 | 0.190 |
Why?
|
| Medicine | 1 | 2023 | 101 | 0.190 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3133 | 0.190 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2022 | 17 | 0.190 |
Why?
|
| Pyelonephritis | 1 | 2022 | 28 | 0.190 |
Why?
|
| Venous Thrombosis | 1 | 2024 | 171 | 0.180 |
Why?
|
| Hypospadias | 1 | 2023 | 77 | 0.180 |
Why?
|
| Pharmacovigilance | 1 | 2022 | 11 | 0.180 |
Why?
|
| Libido | 2 | 2024 | 34 | 0.180 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 156 | 0.180 |
Why?
|
| Counseling | 2 | 2022 | 237 | 0.180 |
Why?
|
| Kidney Calculi | 1 | 2022 | 38 | 0.180 |
Why?
|
| Orchitis | 1 | 2021 | 2 | 0.180 |
Why?
|
| Ureteroscopy | 1 | 2021 | 17 | 0.180 |
Why?
|
| World Health Organization | 2 | 2020 | 115 | 0.180 |
Why?
|
| Pulmonary Embolism | 1 | 2024 | 191 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 1248 | 0.180 |
Why?
|
| Spermatids | 1 | 2021 | 25 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2021 | 77 | 0.170 |
Why?
|
| Ureteral Obstruction | 1 | 2022 | 92 | 0.170 |
Why?
|
| Self-Injurious Behavior | 1 | 2022 | 64 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 154 | 0.170 |
Why?
|
| Evaluation Studies as Topic | 1 | 2021 | 231 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 351 | 0.170 |
Why?
|
| Virus Diseases | 1 | 2023 | 284 | 0.170 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 240 | 0.170 |
Why?
|
| Urethra | 1 | 2021 | 58 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2025 | 480 | 0.160 |
Why?
|
| Mammals | 1 | 2022 | 253 | 0.160 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 22 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2024 | 335 | 0.160 |
Why?
|
| Siblings | 2 | 2021 | 204 | 0.160 |
Why?
|
| Infertility | 1 | 2021 | 73 | 0.160 |
Why?
|
| Coronavirus | 1 | 2020 | 27 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2025 | 492 | 0.160 |
Why?
|
| Radiation Exposure | 1 | 2020 | 45 | 0.160 |
Why?
|
| Dronabinol | 1 | 2020 | 30 | 0.160 |
Why?
|
| Dermatology | 1 | 2020 | 31 | 0.150 |
Why?
|
| Paternal Age | 1 | 2019 | 16 | 0.150 |
Why?
|
| Oocytes | 1 | 2021 | 272 | 0.150 |
Why?
|
| Blastocyst | 1 | 2019 | 73 | 0.150 |
Why?
|
| Suicide | 1 | 2022 | 198 | 0.150 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2019 | 39 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 497 | 0.150 |
Why?
|
| Psychotropic Drugs | 1 | 2020 | 116 | 0.150 |
Why?
|
| Cryptorchidism | 1 | 2019 | 37 | 0.150 |
Why?
|
| Trisomy | 1 | 2019 | 112 | 0.150 |
Why?
|
| North America | 1 | 2019 | 259 | 0.140 |
Why?
|
| Urological Agents | 1 | 2018 | 5 | 0.140 |
Why?
|
| Thyroid Diseases | 1 | 2018 | 28 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 324 | 0.140 |
Why?
|
| Students, Medical | 2 | 2020 | 348 | 0.140 |
Why?
|
| Risk | 2 | 2019 | 734 | 0.140 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2018 | 40 | 0.140 |
Why?
|
| Europe | 1 | 2019 | 368 | 0.140 |
Why?
|
| Cachexia | 1 | 2018 | 57 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2023 | 6491 | 0.140 |
Why?
|
| Thyroid Hormones | 1 | 2018 | 54 | 0.140 |
Why?
|
| Occupational Diseases | 1 | 2019 | 79 | 0.140 |
Why?
|
| Prostatitis | 1 | 2018 | 19 | 0.140 |
Why?
|
| Chronobiology Disorders | 1 | 2018 | 8 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2018 | 42 | 0.140 |
Why?
|
| Men's Health | 1 | 2018 | 22 | 0.140 |
Why?
|
| Microsurgery | 1 | 2018 | 65 | 0.140 |
Why?
|
| Insemination, Artificial | 1 | 2017 | 11 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 327 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 169 | 0.130 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2017 | 11 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2021 | 1514 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 576 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 207 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2024 | 692 | 0.130 |
Why?
|
| Nephrectomy | 1 | 2018 | 157 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 735 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 732 | 0.130 |
Why?
|
| Patient Preference | 1 | 2019 | 148 | 0.130 |
Why?
|
| Scrotum | 1 | 2016 | 27 | 0.120 |
Why?
|
| Abdominal Wall | 1 | 2016 | 26 | 0.120 |
Why?
|
| Comorbidity | 2 | 2018 | 1598 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 205 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 413 | 0.120 |
Why?
|
| Simulation Training | 1 | 2018 | 169 | 0.110 |
Why?
|
| Pedigree | 1 | 2019 | 1684 | 0.110 |
Why?
|
| Sleep | 1 | 2018 | 373 | 0.110 |
Why?
|
| Time Factors | 3 | 2025 | 6231 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 546 | 0.110 |
Why?
|
| Binding Sites | 1 | 2017 | 1143 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2016 | 446 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 752 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 3059 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 419 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 697 | 0.100 |
Why?
|
| Age Factors | 2 | 2019 | 2851 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 643 | 0.100 |
Why?
|
| DNA | 1 | 2019 | 1413 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 1386 | 0.100 |
Why?
|
| Family | 1 | 2017 | 586 | 0.100 |
Why?
|
| Melanoma | 1 | 2020 | 920 | 0.100 |
Why?
|
| Prosthesis Design | 3 | 2020 | 616 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2017 | 703 | 0.090 |
Why?
|
| Prenatal Diagnosis | 1 | 2016 | 650 | 0.090 |
Why?
|
| Estrogens | 2 | 2024 | 432 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2018 | 1054 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2024 | 1685 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8568 | 0.070 |
Why?
|
| Biomarkers | 1 | 2017 | 3403 | 0.070 |
Why?
|
| Nutrition Surveys | 2 | 2020 | 327 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6797 | 0.070 |
Why?
|
| Linear Models | 2 | 2019 | 690 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 4042 | 0.060 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2025 | 7 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 1387 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 3717 | 0.060 |
Why?
|
| Child | 3 | 2023 | 26220 | 0.050 |
Why?
|
| Premenopause | 1 | 2024 | 38 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2025 | 300 | 0.050 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2023 | 48 | 0.050 |
Why?
|
| Sterilization, Reproductive | 1 | 2023 | 5 | 0.050 |
Why?
|
| Mastectomy | 1 | 2023 | 75 | 0.050 |
Why?
|
| Baltimore | 1 | 2023 | 43 | 0.050 |
Why?
|
| Prolapse | 1 | 2023 | 10 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2023 | 80 | 0.050 |
Why?
|
| Menopause | 1 | 2023 | 87 | 0.050 |
Why?
|
| Genitalia | 1 | 2022 | 39 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2023 | 80 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1079 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 31 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2021 | 40 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 41 | 0.040 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2020 | 26 | 0.040 |
Why?
|
| Klinefelter Syndrome | 1 | 2020 | 20 | 0.040 |
Why?
|
| Pain Management | 1 | 2023 | 197 | 0.040 |
Why?
|
| Animals | 1 | 2022 | 34000 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 204 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2313 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2020 | 62 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 27 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2020 | 83 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 309 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2023 | 732 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5246 | 0.040 |
Why?
|
| Oocyte Donation | 1 | 2019 | 4 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2025 | 552 | 0.040 |
Why?
|
| Birth Rate | 1 | 2019 | 15 | 0.040 |
Why?
|
| Pinch Strength | 1 | 2019 | 4 | 0.040 |
Why?
|
| Preimplantation Diagnosis | 1 | 2019 | 25 | 0.040 |
Why?
|
| Prostate | 1 | 2021 | 409 | 0.040 |
Why?
|
| Reproductive Health Services | 1 | 2019 | 23 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1490 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 239 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 254 | 0.030 |
Why?
|
| Fathers | 1 | 2019 | 73 | 0.030 |
Why?
|
| Testis | 1 | 2020 | 399 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 552 | 0.030 |
Why?
|
| Internationality | 1 | 2019 | 128 | 0.030 |
Why?
|
| Urban Population | 1 | 2020 | 274 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 250 | 0.030 |
Why?
|
| Rural Population | 1 | 2020 | 266 | 0.030 |
Why?
|
| Endothelin-1 | 1 | 2017 | 40 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2018 | 107 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 426 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 97 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 561 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2017 | 127 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1281 | 0.030 |
Why?
|
| Stents | 1 | 2022 | 784 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1625 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 566 | 0.030 |
Why?
|
| Mothers | 1 | 2019 | 369 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 380 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1241 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1815 | 0.030 |
Why?
|
| Aging | 1 | 2023 | 1255 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 414 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1896 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 680 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 642 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1241 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 325 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 450 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 722 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1625 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2017 | 686 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3417 | 0.020 |
Why?
|
| Stem Cells | 1 | 2018 | 713 | 0.020 |
Why?
|
| Kidney | 1 | 2018 | 1287 | 0.020 |
Why?
|
| Texas | 1 | 2019 | 3624 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 3417 | 0.020 |
Why?
|